Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Carcinoma, Renal Cell"
Show Display Options
Rank Status Study
1 Not yet recruiting Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Procedure: Nephrectomy
2 Recruiting Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
Conditions: Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Procedure: Arterial Spin Labeling Magnetic Resonance Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Perfusion Magnetic Resonance Imaging
3 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
4 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
5 Recruiting PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Melanoma
Intervention:
6 Recruiting Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza

Study has passed its completion date and status has not been verified in more than two years.